Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'
August 26, 2026 9:22 AM
Piper Sandler analyst Allison M. Bratzel reiterated an Overweight rating and $88.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
